General Information of Drug (ID: DMK4GIS)

Drug Name
Anti-hCD70 CAR transduced PBL Drug Info
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 1 [1]
Pancreatic cancer 2C10 Phase 1 [1]
Renal cell carcinoma 2C90 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMK4GIS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting CD70 antigen (CD27-L)
Drug Name Drug ID Indication ICD 11 Highest Status REF
JNJ-74494550 DM3ICO6 Myelodysplastic syndrome 2A37 Phase 2 [2]
4SCAR19 and 4SCAR70 DMKC8F9 B-cell lymphoma 2A86 Phase 1/2 [3]
MDX-1203 DM0RIQF Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
MDX-1411 DM3402P Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
BMS-936561 DMYIBFM Haematological malignancy 2B33.Y Phase 1 [6]
SGN-70 DMXA7W9 Autoimmune diabetes 5A10 Phase 1 [7]
SGN-CD70A DMMJ1PO Non-hodgkin lymphoma 2B33.5 Phase 1 [8]
AMG 172 DMS72GN Renal cell carcinoma 2C90 Phase 1 [9]
SEA-CD70 DMX94YF Acute myeloid leukaemia 2A60 Phase 1 [10]
CTX130 DM926CH T-cell lymphoma 2A90 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CD70 antigen (CD27-L) TTNCIE0 CD70_HUMAN CAR-T-Cell-Therapy [1]

References

1 ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
2 Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020 Sep;26(9):1459-1467.
3 ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
4 J Clin Oncol 32:5s, 2014 (suppl; abstr 2558).
5 Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol. 2009 Sep;27(9):781-3.
6 Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacok... Biopharm Drug Dispos. 2016 Mar;37(2):93-106.
7 2011 Pipeline of Seattle Genetics.
8 SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). Cancer Research 10/2014; 74(19 Supplement):2647-2647.
9 National Cancer Institute Drug Dictionary (drug id 721679).
10 Clinical pipeline report, company report or official report of Seagen.
11 Clinical pipeline report, company report or official report of CRISPR Therapeutics.